|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shah SA, Cleary SP, Wei AC, Yang I, Taylor
BR, Hemming AW, Langer B, Grant DR, Greig PD and Gallinger S:
Recurrence after liver resection for hepatocellular carcinoma: Risk
factors, treatment, and outcomes. Surgery. 141:330–339. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Regimbeau JM, Abdalla EK, Vauthey JN,
Lauwers GY, Durand F, Nagorney DM, Ikai I, Yamaoka Y and Belghiti
J: Risk factors for early death due to recurrence after liver
resection for hepatocellular carcinoma: Results of a multicenter
study. J Surg Oncol. 85:36–41. 2004. View Article : Google Scholar
|
|
4
|
Cha C, Fong Y, Jarnagin WR, Blumgart LH
and DeMatteo RP: Predictors and patterns of recurrence after
resection of hepatocellular carcinoma. J Am Coll Surg. 197:753–758.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cucchetti A, Piscaglia F, Caturelli E,
Benvegnù L, Vivarelli M, Ercolani G, Cescon M, Ravaioli M, Grazi
GL, Bolondi L, et al: Comparison of recurrence of hepatocellular
carcinoma after resection in patients with cirrhosis to its
occurrence in a surveilled cirrhotic population. Ann Surg Oncol.
16:413–422. 2009. View Article : Google Scholar
|
|
6
|
Yeatman TJ: A renaissance for SRC. Nat Rev
Cancer. 4:470–480. 2004. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Haura EB, Tanvetyanon T, Chiappori A,
Williams C, Simon G, Antonia S, Gray J, Litschauer S, Tetteh L,
Neuger A, et al: Phase I/II study of the Src inhibitor dasatinib in
combination with erlotinib in advanced non-small-cell lung cancer.
J Clin Oncol. 28:1387–1394. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hiscox S, Jordan NJ, Smith C, James M,
Morgan L, Taylor KM, Green TP and Nicholson RI: Dual targeting of
Src and ER prevents acquired antihormone resistance in breast
cancer cells. Breast Cancer Res Treat. 115:57–67. 2009. View Article : Google Scholar
|
|
9
|
Finn RS: Targeting Src in breast cancer.
Ann Oncol. 19:1379–1386. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wiener JR, Nakano K, Kruzelock RP, Bucana
CD, Bast RC Jr and Gallick GE: Decreased Src tyrosine kinase
activity inhibits malignant human ovarian cancer tumor growth in a
nude mouse model. Clin Cancer Res. 5:2164–2170. 1999.PubMed/NCBI
|
|
11
|
Ito H, Gardner-Thorpe J, Zinner MJ, Ashley
SW and Whang EE: Inhibition of tyrosine kinase Src suppresses
pancreatic cancer invasiveness. Surgery. 134:221–226. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bolen JB, Veillette A, Schwartz AM, DeSeau
V and Rosen N: Activation of pp60c-src protein kinase activity in
human colon carcinoma. Proc Natl Acad Sci USA. 84:2251–2255. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cartwright CA, Kamps MP, Meisler AI, Pipas
JM and Eckhart W: pp60c-src activation in human colon carcinoma. J
Clin Invest. 83:2025–2033. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Humar B, Fukuzawa R, Blair V, Dunbier A,
More H, Charlton A, Yang HK, Kim WH, Reeve AE, Martin I, et al:
Destabilized adhesion in the gastric proliferative zone and c-Src
kinase activation mark the development of early diffuse gastric
cancer. Cancer Res. 67:2480–2489. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Summy JM and Gallick GE: Src family
kinases in tumor progression and metastasis. Cancer Metastasis Rev.
22:337–358. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Biscardi JS, Ishizawar RC, Silva CM and
Parsons SJ: Tyrosine kinase signalling in breast cancer: Epidermal
growth factor receptor and c-Src interactions in breast cancer.
Breast Cancer Res. 2:203–210. 2000. View
Article : Google Scholar
|
|
17
|
Rajeshkumar NV, Tan AC, De Oliveira E,
Womack C, Wombwell H, Morgan S, Warren MV, Walker J, Green TP,
Jimeno A, et al: Antitumor effects and biomarkers of activity of
AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res.
15:4138–4146. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hiscox S, Morgan L, Green TP, Barrow D,
Gee J and Nicholson RI: Elevated Src activity promotes cellular
invasion and motility in tamoxifen resistant breast cancer cells.
Breast Cancer Res Treat. 97:263–274. 2006. View Article : Google Scholar
|
|
19
|
Fury MG, Baxi S, Shen R, Kelly KW, Lipson
BL, Carlson D, Stambuk H, Haque S and Pfister DG: Phase II study of
saracatinib (AZD0530) for patients with recurrent or metastatic
head and neck squamous cell carcinoma (HNSCC). Anticancer Res.
31:249–253. 2011.PubMed/NCBI
|
|
20
|
Edwards J: Src kinase inhibitors: An
emerging therapeutic treatment option for prostate cancer. Expert
Opin Investig Drugs. 19:605–614. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li Y, Tang Z, Ye S, Liu Y, Chen J, Xue Q,
Huang X, Chen J, Bao W, Yang J, et al: Establishment of human
hepatocellular carcinoma cell line with spontaneous pulmonary
metastasis through in vivo selection. Zhonghua Yi Xue Za Zhi.
82:601–605. 2002.In Chinese. PubMed/NCBI
|
|
22
|
Qian YB, Zhang JB, Wu WZ, Fang HB, Jia WD,
Zhuang PY, Zhang BH, Pan Q, Xu Y, Wang L, et al: P48 is a
predictive marker for outcome of postoperative interferon-alpha
treatment in patients with hepatitis B virus infection-related
hepatocellular carcinoma. Cancer. 107:1562–1569. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bjelfman C, Hedborg F, Johansson I,
Nordenskjöld M and Påhlman S: Expression of the neuronal form of
pp60c-src in neuroblastoma in relation to clinical stage and
prognosis. Cancer Res. 50:6908–6914. 1990.PubMed/NCBI
|
|
24
|
Chang YM, Bai L, Liu S, Yang JC, Kung HJ
and Evans CP: Src family kinase oncogenic potential and pathways in
prostate cancer as revealed by AZD0530. Oncogene. 27:6365–6375.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Frame MC: Src in cancer: Deregulation and
consequences for cell behaviour. Biochim Biophys Acta.
1602:114–130. 2002.PubMed/NCBI
|
|
26
|
Roy S, Ruest PJ and Hanks SK: FAK
regulates tyrosine phosphorylation of CAS, paxillin, and PYK2 in
cells expressing v-Src, but is not a critical determinant of v-Src
transformation. J Cell Biochem. 84:377–388. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Frame MC: Newest findings on the oldest
oncogene; How activated src does it. J Cell Sci. 117:989–998. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mitra SK and Schlaepfer DD:
Integrin-regulated FAK-Src signaling in normal and cancer cells.
Curr Opin Cell Biol. 18:516–523. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Brunton VG and Frame MC: Src and focal
adhesion kinase as therapeutic targets in cancer. Curr Opin
Pharmacol. 8:427–432. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Serrels A, McLeod K, Canel M, Kinnaird A,
Graham K, Frame MC and Brunton VG: The role of focal adhesion
kinase catalytic activity on the proliferation and migration of
squamous cell carcinoma cells. Int J Cancer. 131:287–297. 2012.
View Article : Google Scholar
|
|
31
|
Rajendran P, Li F, Shanmugam MK, Vali S,
Abbasi T, Kapoor S, Ahn KS, Kumar AP and Sethi G: Honokiol inhibits
signal transducer and activator of transcription-3 signaling,
proliferation, and survival of hepatocellular carcinoma cells via
the protein tyrosine phosphatase SHP-1. J Cell Physiol.
227:2184–2195. 2012. View Article : Google Scholar
|
|
32
|
Zheng F, Liao YJ, Cai MY, Liu YH, Liu TH,
Chen SP, Bian XW, Guan XY, Lin MC, Zeng YX, et al: The putative
tumour suppressor microRNA-124 modulates hepatocellular carcinoma
cell aggressiveness by repressing ROCK2 and EZH2. Gut. 61:278–289.
2012. View Article : Google Scholar
|
|
33
|
Hsieh SY, He JR, Hsu CY, Chen WJ, Bera R,
Lin KY, Shih TC, Yu MC, Lin YJ, Chang CJ, et al:
Neuregulin/erythroblastic leukemia viral oncogene homolog 3
autocrine loop contributes to invasion and early recurrence of
human hepatoma. Hepatology. 53:504–516. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yoo BK, Emdad L, Gredler R, Fuller C,
Dumur CI, Jones KH, Jackson-Cook C, Su ZZ, Chen D, Saxena UH, et
al: Transcription factor Late SV40 Factor (LSF) functions as an
oncogene in hepatocellular carcinoma. Proc Natl Acad Sci USA.
107:8357–8362. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tan FL, Ooi A, Huang D, Wong JC, Qian CN,
Chao C, Ooi L, Tan YM, Chung A, Cheow PC, et al: p38delta/MAPK13 as
a diagnostic marker for cholangiocarcinoma and its involvement in
cell motility and invasion. Int J Cancer. 126:2353–2361. 2010.
|
|
36
|
Carretero J, Shimamura T, Rikova K,
Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA,
McNamara KL, Brandstetter KA, et al: Integrative genomic and
proteomic analyses identify targets for Lkb1-deficient metastatic
lung tumors. Cancer Cell. 17:547–559. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Byers LA, Sen B, Saigal B, Diao L, Wang J,
Nanjundan M, Cascone T, Mills GB, Heymach JV and Johnson FM:
Reciprocal regulation of c-Src and STAT3 in non-small cell lung
cancer. Clin Cancer Res. 15:6852–6861. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tryfonopoulos D, Walsh S, Collins DM,
Flanagan L, Quinn C, Corkery B, McDermott EW, Evoy D, Pierce A,
O'Donovan N, et al: Src: A potential target for the treatment of
triple-negative breast cancer. Ann Oncol. 22:2234–2240. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Puls LN, Eadens M and Messersmith W:
Current status of SRC inhibitors in solid tumor malignancies.
Oncologist. 16:566–578. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hannon RA, Finkelman RD, Clack G, Iacona
RB, Rimmer M, Gossiel F, Baselga J and Eastell R: Effects of Src
kinase inhibition by saracatinib (AZD0530) on bone turnover in
advanced malignancy in a Phase I study. Bone. 50:885–892. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Gucalp A, Sparano JA, Caravelli J,
Santamauro J, Patil S, Abbruzzi A, Pellegrino C, Bromberg J, Dang
C, Theodoulou M, et al: Phase II trial of saracatinib (AZD0530), an
oral SRC-inhibitor for the treatment of patients with hormone
receptor-negative metastatic breast cancer. Clin Breast Cancer.
11:306–311. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Guo C, Liu QG, Yang W, Zhang ZL and Yao
YM: Relation among p130Cas, E-cadherin and beta-catenin expression,
clinicopathologic significance and prognosis in human
hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int.
7:490–496. 2008.PubMed/NCBI
|
|
43
|
Ito Y, Kawakatsu H, Takeda T, Sakon M,
Nagano H, Sakai T, Miyoshi E, Noda K, Tsujimoto M, Wakasa K, et al:
Activation of c-Src gene product in hepatocellular carcinoma is
highly correlated with the indices of early stage phenotype. J
Hepatol. 35:68–73. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lau GM, Lau GM, Yu GL, Gelman IH, Gutowski
A, Hangauer D and Fang JW: Expression of Src and FAK in
hepatocellular carcinoma and the effect of Src inhibitors on
hepatocellular carcinoma in vitro. Dig Dis Sci. 54:1465–1474. 2009.
View Article : Google Scholar
|
|
45
|
Rajendran P, Ong TH, Chen L, Li F,
Shanmugam MK, Vali S, Abbasi T, Kapoor S, Sharma A, Kumar AP, et
al: Suppression of signal transducer and activator of transcription
3 activation by butein inhibits growth of human hepatocellular
carcinoma in vivo. Clin Cancer Res. 17:1425–1439. 2011. View Article : Google Scholar
|
|
46
|
Zhang S, Huang WC, Li P, Guo H, Poh SB,
Brady SW, Xiong Y, Tseng LM, Li SH, Ding Z, et al: Combating
trastuzumab resistance by targeting SRC, a common node downstream
of multiple resistance pathways. Nat Med. 17:461–469. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Guarino M: Src signaling in cancer
invasion. J Cell Physiol. 223:14–26. 2010.PubMed/NCBI
|
|
48
|
Kim LC, Song L and Haura EB: Src kinases
as therapeutic targets for cancer. Nat Rev Clin Oncol. 6:587–595.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Simpkins F, Hevia-Paez P, Sun J, Ullmer W,
Gilbert CA, da Silva T, Pedram A, Levin ER, Reis IM, Rabinovich B,
et al: Src Inhibition with saracatinib reverses fulvestrant
resistance in ER-positive ovarian cancer models in vitro and in
vivo. Clin Cancer Res. 18:5911–5923. 2012. View Article : Google Scholar : PubMed/NCBI
|
